AVAX Technologies to Present at Bio-Europe 2005 International Partnering Conference

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company with operationsin the United States and Europe. The Company is engaged in theresearch, clinical and commercial development of biological productsand cancer therapeutics. AVAX's AC Vaccine platform is a therapeutictreatment for cancer. In addition, the Company performscontract-manufacturing services for biological products to otherpharmaceutical and biotechnology companies.

The AC Vaccines are prepared by attaching a small chemical to thepatients tumor cells in a process known as haptenization. This haptenmodification allows the tumor cells to stimulate a T cell-based immuneresponse to a patients own tumor cells. An early indicator of T cellimmune activity is delayed type hypersensitivity (DTH). A previouslypublished article in the Journal of Clinical Oncology, February 2004reported actual five-year survival data for a group of 214 patientswith clinically evident Stage III melanoma treated with the AC Vaccinefollowing surgery. The study demonstrated five-year survival of 45%and showed a highly statistically significant relationship betweensurvival and DTH to patients' own tumor cells. Notably, based uponthese results, DTH appears to be a viable "surrogate marker" forsurvival and an early indicator for clinical effectiveness of currentand future product candidates. Previously clinical trials in ovarianand renal cell carcinoma, demonstrated strong DTH responses consistentwith those reported for melanoma patients.

Except for statements that are historical, the statements in thisrelease are "forward-looking" statements that are made pursuant to thesafe harbor provisions of Section 27A of the Securities Act of 1933and Section 21E of the Securities Exchange Act of 1934.Forward-looking statements involve significant risks anduncertainties, and in light of the significant uncertainties inherentin such statements, the inclusion of such information should not beregarded as a representation by AVAX that the objectives and plans ofthe Company will be achieved. In fact, actual results could differmaterially from those contemplated by such forward-looking statements.Many important factors affect the Company's prospects, including (1)receipt of the balance of the funds from the private placementtransaction and in the future to obtain substantial additional funds,beyond the announced private placement, (2) the results of clinicaland laboratory testing of its vaccine technologies, (3) possiblefuture FDA or AFSSAPS questions regarding the Company's products andmanufacturing processes, (4) the Company's ability to maintain itsrights under license agreements and to meet funding requirements underits license agreements, (5) the Company's ability to demonstrate thesafety and efficacy of product candidates at each stage of developmentand to meet applicable regulatory standards and receive requiredregulatory approvals, as well as other risks detailed from time totime in AVAX's public disclosure filings with the Securities andExchange Commission, including its prospectus forming a part of theCompany's registration statement on form SB-2 filed November 8, 2005and its Annual Report on Form 10-KSB for the year ended December 31,2003. AVAX does not undertake any obligation to release publicly anyrevisions to these forward-looking statements or to reflect theoccurrence of unanticipated events.